The European Medicine Agency (EMA) has established ‘eligibility criteria’ in order to make sure that it only establishes dialogues with the most suitable organisations that act in the interests of European patients, consumers and healthcare professionals. The European Association of Urology would like to engage in dialogue with the EMA and has provided the following information for the evaluation of eligibility.
As part of the evaluation for eligibility, the European Association of Urology has provided the following financial information (2022) to be assessed by the parameters as set by the European Medicine Agency:
Income from industry:
- Registration fees - 32.52%
- Publications - 10.32%
- Membership fees - 9.48%
- Accounting and management consulting - 0.74%
- Other income - 0.10%
|Overall proportion of industry and non-industry:||46.84% vs 53.16%|
The following pharmaceutical companies provide funding to EAU:
- Janssen Pharmaceutical N.V.
- Astellas Pharma Europe Ltd
- IPSEN Innovation SAS
- GSK Services Unlimited
- AstraZeneca UK Ltd.
- Telix Innovations SA
- Pierre Fabre SA
- Bayer Healthcare Pharmaceuticals, Inc.Pfizer Inc.
- Merck Sharp & Dohme LLC
The following medtech companies provide funding to EAU:
- Olympus Europa SE & CO. KG
- Intuitive Surgical Sarl
- Covidien AG
- Boston Scientific International S.A.
- Karl Storz SE & Co. KG
- Coloplast Manufacturing France
- Cook Medical Europe Ltd.
- Quanta System SPA
- Medac GmbH
- Richard Wolf GmbH
The highest contribution from a single company is less than 3.65% of the organisation’s total income. The financial Annual Report of 2022 by EAU can be found here: Compilation Report.
In order to ensure good governance, interactions should be based on fundamental principles of integrity, mutual respect, responsiveness, accountability, collaboration and transparency. The EAU Code of Ethics set standards for industry partners with regard to ethical interactions with the healthcare community. In order to make funding partnerships work in practice, to ensure the integrity of both the funder and EAU is maintained, and to demonstrate to other stakeholders that our relationships are absolutely scrupulous, the following key principles underpin our acceptance of funding.